Revlimid Lax Teratogenicity Studies Led To Broad Risk Management Plan – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An inadequate reproductive safety assessment of Celgene’s Revlimid was of central concern to FDA during its review of the myelodysplastic syndromes treatment and helped guide post-approval risk management requirements, review documents show.